restructuring
The firm is aiming to break even on its cash flow by 2027 by narrowing its focus on its sarcoma treatments and pipeline candidates with the greatest potential.
Galapagos Splitting Into Two Companies, Cutting 300 Jobs, Altering Gilead Licensing Deal
The changes will result in one company focused exclusively on cancer cell therapies and another on strategic transactions to build a pipeline of innovative medicines.
Gilead Sciences to Lay Off 72 Employees, Shutter Seattle Office
The cuts, which will go into effect mid-January, come a year after the drugmaker slashed 7 percent of the workforce at Kite Pharma, its cell therapy business.
Viracta Therapeutics Cutting 42 Percent of Workforce, Reducing Board Seats in Restructuring
The restructuring is aimed at freeing up resources so the firm can advance its EBV-positive peripheral T-cell lymphoma drug toward the market.
Black Diamond Therapeutics Restructures Workforce, Deprioritizes RAF Program
The firm is focusing its resources on developing its lead candidate, the EGFR inhibitor BDTX-1535, which is undergoing testing in EGFR-mutated NSCLC.